FCA
TGTX icon

Fortis Capital Advisors’s TG Therapeutics TGTX Stock Holding History

Fortis Capital Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-396
Closed -$5.96K – 568
2023
Q1 		$5.96K Hold
396
– – ﹤0.01% 490
2022
Q4 		$4.68K Buy
+396
New +$2.87K ﹤0.01% 520

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Fortis Capital Advisors's TGTX Position: Q2 2023 in Review

Fortis Capital Advisors sold out of TG Therapeutics (TGTX) in Q2 2023, closing a stake of 396 shares — an estimated $5.96K sold.

Fortis Capital Advisors first reported a position in TGTX in Q4 2022 and held it in 2 quarters. The position peaked at $5.96K in Q1 2023. 244 funds tracked by Wall St. Rank hold TGTX as of Q2 2023.

  • Fortis Capital Advisors reported no remaining TG Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Fortis Capital Advisors sold 396 TG Therapeutics shares in Q2 2023, an estimated $5.96K.
  • Fortis Capital Advisors first reported a position in TG Therapeutics in Q4 2022 and held it in 2 quarters.
  • Fortis Capital Advisors's TG Therapeutics position peaked at $5.96K in Q1 2023.
  • 244 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2023.

Based on Fortis Capital Advisors's 13F filing for Q2 2023, filed 15 Aug 2023.